ENG
Anemia Treatment Market: Global Industry Analysis and Forecast (2024-2030) by Product Type, Gender, Formulation, and, Region
The Anemia Treatment Market size was valued at US$ 12.20 Billion in 2023 and the Anemia Treatment revenue is expected to grow at 6.9 % through 2024 to 2030, reaching nearly US$ 19.47 Billion.
Format : PDF | Report ID : SMR_496
Anemia Treatment Market Definition & Overview:
Anemia is a condition in which the body lacks red blood cells or hemoglobin. The function of red blood cells is to transport oxygen from the lungs to the rest of the body. Anemia symptoms include weakness, fatigue, and shortness of breath, and physical activity limits, which might vary according to age, altitude, smoking habits, sex, and pregnancy status. If left untreated, anemia can lead to death. The anemia treatment market report has come with PESTLE analysis, PORTER's five force analysis and segment analysis on the basis of anemia, drug, distribution channel and region.
To get more Insights: Request Free Sample Report
Anemia Treatment Market Dynamics:
According to the WHO, anemia afflicted roughly 56 percent of individuals worldwide in 2018. With the right medication, anemia can be effectively addressed. One of the most important driving factors in the anemia treatment market is the high occurrence of nutritional insufficiency. Iron insufficiency owing to inadequate iron consumption is responsible for 50% of anemic cases, according to the WHO. The anemia treatment market is being fuelled by a growing baby boom population as well as an increase in chronic illnesses and disorders. In developing countries, a poor nutritional diet also enhances this market.
The most prevalent kind of anemia is iron-deficiency anemia, which occurs when the blood lacks enough red blood cells to transport oxygen to the body's tissues. Iron Deficiency Anemia, according to the National Institute of Health, is one of the most common nutritional deficiency conditions, affecting substantial segments of the population, notably physiological groups such as children, menstrual women, and pregnant women. Iron deficiency anemia is also a problem in Asian countries like India and China, where the condition is becoming more prevalent among women. As a result, it is expected that the anemia treatment market would grow steadily throughout the forecast period.
Anemia Treatment Market Segment Analysis:
By Drug, Corticosteroids and immunosuppressants accounted for more than half of all prescriptions in 2020. These segments are being driven by rising anemia awareness and rising initiatives by non-government organizations and the government, rising anemia prevalence, and developments in the anemia treatment market's research activities.
By Distribution Channel, E-commerce, hospital pharmacies, and retail pharmacies are all part of the anemia therapy business. A significant portion of the worldwide market was accounted for by retail pharmacies. In terms of CAGR, the e-commerce segment is expected to grow at the fastest rate in the world.
Anemia Treatment Market Regional Insights:
Because of the early introduction of highly developed treatment options, rising nutritional deficit due to changing lifestyles, and the continual adoption of advantageous reimbursement policies, North America is expected to lead the worldwide anemia treatment market. Iron deficiency affects roughly 2% of adult males and 9–12% of adult women in the United States, according to family doctors.
Over the forecast period, the Asia Pacific anemia treatment market is expected to rise at a significant rate. This is due to the region's large anemic patient population, rising knowledge of anemia diagnosis and treatment, different government anemia programs, and ongoing research and development. According to the SCDC, India set a global record in 2016 by screening 7.5 million people for SCD in a single day, thanks to government and non-government groups' awareness programs.
The objective of the report is to present a comprehensive analysis of the Anemia Treatment Market to the stakeholders in the industry. The report provides trends that are most dominant in the Anemia Treatment Market and how these trends will influence new business investments and market development throughout the forecast period. The report also aids in the comprehension of the market dynamics and competitive structure of the market by analyzing market leaders, market followers, and regional players.
The qualitative and quantitative data provided in the Anemia Treatment Market report is to help understand which market segments, regions are expected to grow at higher rates, factors affecting the market, and key opportunity areas, which will drive the industry and market growth through the forecast period. The report also includes the competitive landscape of key players in the industry along with their recent developments in the Anemia Treatment Market. The report studies factors such as company size, market share, market growth, revenue, production volume, and profits of the key players in the market.
The report provides Porter's Five Force Model, which helps in designing the business strategies in the market. The report helps in identifying how many rivals are existing, who they are, and how their product quality is in the Market. The report also analyses if the Anemia Treatment Market is easy for a new player to gain a foothold in the market, do they enter or exit the market regularly if the market is dominated by a few players, etc.
Anemia Treatment Market Scope:
|
Anemia Treatment Market |
|
|
Market Size in 2023 |
USD 12.20 Bn. |
|
Market Size in 2030 |
USD 19.47 Bn. |
|
CAGR (2024-2030) |
6.9% |
|
Historic Data |
2018-2022 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2030 |
|
Segment Scope |
By Anemia
|
|
By Drug
|
|
|
By Distribution Channel
|
|
|
Regional Scope |
North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America |
Anemia Treatment Market Players:
- Pfizer (USA)
- Novartis (Switzerland)
- Roche (Switzerland)
- Amgen (USA)
- Bayer (Germany)
- Glaxosmithkline (UK)
- Teva Pharmaceuticals (Jerusalem)
- Novo Nordisk (Denmark)
- AMAG Pharmaceuticals (USA)
- Rockwell Medicines (Michigan)
- Akebia Therapeutics (USA)
- Vifor Pharma (Switzerland)
Frequently Asked Questions
One of the most important driving factors in the anemia treatment market is the high occurrence of nutritional insufficiency.
North America is expected to lead the worldwide anemia treatment market.
This is due to the region's large anemic patient population, rising knowledge of anemia diagnosis and treatment, different government anemia programs, and ongoing research and development.
Pfizer (USA), Novartis (Switzerland), Roche (Switzerland), Amgen (USA), and Bayer (Germany).
Chapter 1 Scope of the Report
Chapter 2 Research Methodology
2.1. Research Process
2.2. Global Anemia Treatment Market: Target Audience
2.3. Global Anemia Treatment Market: Primary Research (As per Client Requirement)
2.4. Global Anemia Treatment Market: Secondary Research
Chapter 3 Executive Summary
Chapter 4 Competitive Landscape
4.1. Market Share Analysis, By Region, 2023-2030(In %)
4.1.1.1. North America Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.2. Europe Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.3. Asia Pacific Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.4. South America Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.5. Middle East and Africa Market Share Analysis, By Value, 2023-2030 (In %)
4.2. Market Dynamics
4.2.1.Market Drivers
4.2.2.Market Restraints
4.2.3.Market Opportunities
4.2.4.Market Challenges
4.2.5.PESTLE Analysis
4.2.6.PORTERS Five Force Analysis
4.2.7.Value Chain Analysis
4.3. Global Anemia Treatment Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.3.1.1. Global Market Share Analysis, By Anemia, 2023-2030 (Value US$ MN)
4.3.1.1.1.Iron Deficiency
4.3.1.1.2.Sickle Cell
4.3.1.1.3.Pernicious
4.3.1.1.4.Thalassemia
4.3.1.1.5.Hemolytic
4.3.1.2. Global Market Share Analysis, By Drug, 2023-2030 (Value US$ MN)
4.3.1.2.1.Bone Marrow Stimulants
4.3.1.2.2.Gene Therap
4.3.1.2.3.Iron Chelating Agents
4.3.1.2.4.Corticosteroids
4.3.1.2.5.Supplements
4.3.1.2.6.Immunotherapy
4.3.1.3. Global Market Share Analysis, By Distribution Channel, 2023-2030 (Value US$ MN)
4.3.1.3.1.Retail Pharmacies
4.3.1.3.2.E-Commerce
4.3.1.3.3.Hospital Pharmacies
4.4. North America Anemia Treatment Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.4.1.1. North America Market Share Analysis, By Anemia, 2023-2030 (Value US$ MN)
4.4.1.1.1.Iron Deficiency
4.4.1.1.2.Sickle Cell
4.4.1.1.3.Pernicious
4.4.1.1.4.Thalassemia
4.4.1.1.5.Hemolytic
4.4.1.2. North America Market Share Analysis, By Drug, 2023-2030 (Value US$ MN)
4.4.1.2.1.Bone Marrow Stimulants
4.4.1.2.2.Gene Therap
4.4.1.2.3.Iron Chelating Agents
4.4.1.2.4.Corticosteroids
4.4.1.2.5.Supplements
4.4.1.2.6.Immunotherapy
4.4.1.3. North America Market Share Analysis, By Distribution Channel, 2023-2030 (Value US$ MN)
4.4.1.3.1.Retail Pharmacies
4.4.1.3.2.E-Commerce
4.4.1.3.3.Hospital Pharmacies
4.4.1.4. North America Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.4.1.4.1.US
4.4.1.4.2.Canada
4.4.1.4.3.Mexico
4.5. Europe Anemia Treatment Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.5.1.1. Europe Market Share Analysis, By Anemia, 2023-2030 (Value US$ MN)
4.5.1.2. Europe Market Share Analysis, By Drug, 2023-2030 (Value US$ MN)
4.5.1.3. Europe Market Share Analysis, By Distribution Channel, 2023-2030 (Value US$ MN)
4.5.1.4. Europe Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.5.1.4.1.UK
4.5.1.4.2.France
4.5.1.4.3.Germany
4.5.1.4.4.Italy
4.5.1.4.5.Spain
4.5.1.4.6.Sweden
4.5.1.4.7.Austria
4.5.1.4.8.Rest Of Europe
4.6. Asia Pacific Anemia Treatment Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.6.1.1. Asia Pacific Market Share Analysis, By Anemia, 2023-2030 (Value US$ MN)
4.6.1.2. Asia Pacific Market Share Analysis, By Drug, 2023-2030 (Value US$ MN)
4.6.1.3. Asia Pacific Market Share Analysis, By Distribution Channel, 2023-2030 (Value US$ MN)
4.6.1.4. Asia Pacific Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.6.1.4.1.China
4.6.1.4.2.India
4.6.1.4.3.Japan
4.6.1.4.4.South Korea
4.6.1.4.5.Australia
4.6.1.4.6.ASEAN
4.6.1.4.7.Rest Of APAC
4.7. South America Anemia Treatment Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.7.1.1. South America Market Share Analysis, By Anemia, 2023-2030 (Value US$ MN)
4.7.1.2. South America Market Share Analysis, By Drug, 2023-2030 (Value US$ MN)
4.7.1.3. South America Market Share Analysis, By Distribution Channel, 2023-2030 (Value US$ MN)
4.7.1.4. South America Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.7.1.4.1.Brazil
4.7.1.4.2.Argentina
4.7.1.4.3.Rest Of South America
4.8. Middle East and Africa Anemia Treatment Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.8.1.1. Middle East and Africa Market Share Analysis, By Anemia, 2023-2030 (Value US$ MN)
4.8.1.2. Middle East and Africa Market Share Analysis, By Drug, 2023-2030 (Value US$ MN)
4.8.1.3. Middle East and Africa Market Share Analysis, By Distribution Channel, 2023-2030 (Value US$ MN)
4.8.1.4. Middle East and Africa Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.8.1.4.1.South Africa
4.8.1.4.2.GCC
4.8.1.4.3.Egypt
4.8.1.4.4.Nigeria
4.8.1.4.5.Rest Of ME&A
Chapter 5 Stellar Competition Matrix
5.1.1.Global Stellar Competition Matrix
5.1.2.North America Stellar Competition Matrix
5.1.3.Europe Stellar Competition Matrix
5.1.4.Asia Pacific Stellar Competition Matrix
5.1.5.South America Stellar Competition Matrix
5.1.6.Middle East and Africa Stellar Competition Matrix
5.2. Key Players Benchmarking
5.2.1.Key Players Benchmarking By Application, Pricing, Market Share, Investments, Expansion Plans, Physical Presence and Presence in the Market.
5.3. Mergers and Acquisitions in Industry
5.3.1.M&A by Region, Value and Strategic Intent
Chapter 6 Company Profiles
6.1. Key Players
6.1.1. Pfizer
6.1.1.1. Company Overview
6.1.1.2. Source Portfolio
6.1.1.3. Financial Overview
6.1.1.4. Business Strategy
6.1.1.5. Key Developments
6.1.2.Pfizer
6.1.3.Novartis
6.1.4.Roche
6.1.5.Amgen
6.1.6.Bayer
6.1.7.Glaxosmithkline
6.1.8.Teva Pharmaceuticals
6.1.9.Novo Nordisk
6.1.10.AMAG Pharmaceuticals
6.1.11.Rockwell Medicines
6.1.12.Akebia Therapeutics
6.1.13.Vifor Pharma
6.2. Key Findings
6.3. Recommendations
